Clinical Trials Using Boron-dipyrromethene-modified Olaparib Fluorescent Imaging Agent

Clinical trials are research studies that involve people. The clinical trials on this list are studying Boron-dipyrromethene-modified Olaparib Fluorescent Imaging Agent. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trial 1 of 1
  • PARPi-FL and Fluorescence Imaging in Detecting Cancer in Patients with Stage I-II Oral Cancer

    This phase I / II trial studies the side effects of and best dose of boron-dipyrromethene-modified olaparib fluorescent imaging agent (PARPi-FL) and fluorescence imaging in detecting cancer in patients with stage I-II oral cancer. PARPi-FL may help surgeons detect cancer of the mouth and tongue, and make it easier for the surgeon to determine the location and size of the cancer.
    Location: Memorial Sloan Kettering Cancer Center, New York, New York